BRCA1 and BRCA2 Mutations in Polish Women with Ductal Carcinoma In Situ
Authors:
- Sylwia FeszakSFSylwia Feszak
- Igor Jarosław FeszakIgor Jarosław Feszak
- Wojciech KluźniakWKWojciech Kluźniak
- Dominika WokołorczykDWDominika Wokołorczyk
- Klaudia StempaKSKlaudia Stempa
- Katarzyna GliniewiczKGKatarzyna Gliniewicz
- Jan UcińskiJUJan Uciński
- Tomasz HuzarskiTHTomasz Huzarski
- Tadeusz DębniakTDTadeusz Dębniak
- Jacek GronwaldJGJacek Gronwald
- Jan LubińskiJLJan Lubiński
- Steven A. NarodSteven A. Narod
Open Access
Abstract
Background/Objectives: Ductal carcinoma in situ (DCIS) is the most common non-invasive form of breast cancer. It is not clear to what extent DCIS is a part of the hereditary breast/ovarian cancer syndrome caused by BRCA1/2 mutations. Therefore, we investigated the association of BRCA1/2 mutations in patients with DCIS and assessed their impact on survival. Methods: We studied 564 Polish women with DCIS for six alleles in BRCA1 (c.181T>G, c.5266dupC, c.4035delA, c.3700_3704del5, c.68_69del and c.5251C>T) and four in BRCA2 (c.658_659del, c.3847_3848del, c.5946del and c.7913_7917del). To investigate the association of BRCA1/2 founder mutations with DCIS risk, we tested 4702 controls as a reference. To analyze survival, mutation carriers were followed for an average of 110 months. Results: A BRCA1 mutation was present in seven (1.24%) cases and in twenty-two (0.47%) controls (OR = 3.27, 95%CI 1.36 to 7.87, p = 0.01). A BRCA2 mutation was present in eight (1.42%) cases versus six (0.13%) controls (OR = 11.3, 95%CI 3.9 to 32.6, p < 0.0001). Three of the fifteen cases with BRCA1/2 mutations developed invasive ipsilateral or contralateral breast cancer, on average 6 years from the diagnosis of DCIS. There were no deaths reported among the 15 mutation carriers with DCIS. Conclusions: DCIS is a part of the hereditary breast/ovarian cancer syndrome caused by BRCA1/2 mutations. Women with DCIS should receive genetic counseling and testing for BRCA1/2 mutations. BRCA1/2 mutations may predispose women to a better DCIS prognosis, but further studies are needed.Keywords
This publication has 47 references indexed in Scilit:
- MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJAMA Oncology, 2024
- Role of Breast MRI in the Evaluation and Detection of DCIS: Opportunities and ChallengesJournal of Magnetic Resonance Imaging, 2019
- The spectrum of mutations predisposing to familial breast cancer in PolandInternational Journal of Cancer, 2019
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancerInternational Journal of Cancer, 2011
- Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In SituJAMA, 2005
- A high proportion of founder BRCA1 mutations in Polish breast cancer familiesInternational Journal of Cancer, 2004
- BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern PolandHuman Mutation, 2003
- High frequency of recurrent mutations inBRCA1 andBRCA2 genes in Polish families with breast and ovarian cancerHuman Mutation, 2000
- Prevalence of BRCA1 founder mutations in western PolandHuman Mutation, 2000